Although AON seems to be a promising approach in dampening DDR1-mediated deleterious effects in mouse models of kidney diseases, whether downregulating DDR1 expression is a feasible treatment option for patients with kidney disease remains to be determined. The gene discussed is DDR1; the disease is kidney disorder.